Author Affiliations: Departments of Dermatology (Drs Baumann Conzett, Kolm, Kamarachev, Dummer, Braun, French, and Hofbauer) and Neurology (Drs Jelcic and Linnebank), Z ürich University Hospital, Z ürich, Switzerland.
The immunosuppressant drug FTY720 inhibits lymphocyte emigration from lymphoid organs.1 The phase III TRANSFORMS trial2 showed no melanomas in 420 patients treated with 1.25-mg/d FTY720, 3 melanomas in 429 patients treated with 0.5-mg/d FTY720, and no melanomas in 431 patients treated with interferon beta-1a.2 In the FREEDOMS trial3 over 24 months, 1 melanoma occurred in 429 patients treated with 1.25-mg/d FTY720, no melanomas in 425 patients treated with0.5-mg/d FTY720, and 1 melanoma in 418 patients taking placebo. A 3-year phase II study showed 1 melanoma in the placebo/FTY720 group after 25 months and 1 melanoma in the 1.25-mg/d FTY720 group after 36 months.
Conzett KB, Kolm I, Jelcic I, Kamarachev J, Dummer R, Braun R, French LE, Linnebank M, Hofbauer GÜFL. Melanoma Occurring During Treatment With Fingolimod for Multiple Sclerosis: A Case Report. Arch Dermatol. 2011;147(8):991-992. doi:10.1001/archdermatol.2011.212